H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The company reported a “somewhat weaker” sales performance in Q4 with the collaboration revenue of Zurzuvae being $11.4M, the analyst tells investors in a research note. The firm says shipments outpace revenues though the Zurzuvae launch doesn’t keep pace with the prior trajectory.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics Reports Strong 2024 Performance
- SAGE Therapeutics: Hold Rating Amid Financial Challenges and Uncertain Outlook
- Sage Therapeutics says existing cash to support operations through mid-2027
- Sage Therapeutics reports Q4 EPS , consensus ($1.36)
- SAGE Earnings Report this Week: Is It a Buy, Ahead of Earnings?